Eversept Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Eversept Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$11.7M	Buy	207,768 +114,020	+122%	+$6.65M	0.62%	39
2025 Q4	$5.57M	Sell	93,748 -52,894	-36%	-$2.88M	0.28%	67
2025 Q3	$7.94M	Buy	+146,642	New	+$8.39M	0.55%	41
2018 Q3	–	Sell	-84,257	Closed	-$7.94M	–	66
2018 Q2	$7.94M	Buy	84,257 +38,257	+83%	+$3.35M	3.63%	8
2018 Q1	$3.73M	Buy	46,000 +300	+0.7%	+$25.7K	1.73%	19
2017 Q4	$4.08M	Buy	+45,700	New	+$3.97M	2.34%	15

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Eversept Partners's BMRN Position: Q1 2026 in Review

Eversept Partners increased its BioMarin Pharmaceuticals (BMRN) stake by 122% in Q1 2026, buying an estimated $6.65M and bringing the position to 207,768 shares worth $11.7M. The position accounts for 0.62% of the portfolio, ranked #39.

Eversept Partners first reported a position in BMRN in Q4 2017 and has held it in 6 quarters since. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Eversept Partners held 207,768 shares of BioMarin Pharmaceuticals worth $11.7M as of Q1 2026.
Eversept Partners bought 114,020 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $6.65M.
BioMarin Pharmaceuticals made up 0.62% of Eversept Partners's portfolio in Q1 2026, its #39 holding.
Eversept Partners first reported a position in BioMarin Pharmaceuticals in Q4 2017 and has held it in 6 quarters since.
554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Eversept Partners's 13F filing for Q1 2026, filed 15 May 2026.